{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:37:35Z","timestamp":1791859055939,"version":"4.3.4"},"reference-count":49,"publisher":"Japanese Society for the Study of Xenobiotics","issue":"4","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2013]]},"DOI":"10.2133\/dmpk.dmpk-12-rg-129","type":"journal-article","created":{"date-parts":[[2013,1,16]],"date-time":"2013-01-16T02:49:27Z","timestamp":1358304567000},"page":"332-338","source":"Crossref","is-referenced-by-count":179,"title":["Cannabidiol Is a Potent Inhibitor of the Catalytic Activity of Cytochrome P450 2C19"],"prefix":"10.2133","volume":"28","author":[{"given":"Rongrong","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yamaori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuka","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuo","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"900","reference":[{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/j.1552-4604.2002.tb05998.x","article-title":"Cannabidiol: an overview of some pharmacological aspects","volume":"42","author":"Mechoulam","year":"2002","journal-title":"J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0010","doi-asserted-by":"crossref","first-page":"21152125","DOI":"10.1016\/j.jacc.2010.07.033","article-title":"Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy","volume":"56","author":"Rajesh","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0015","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2011.52","article-title":"Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis","volume":"2","author":"Lim","year":"2011","journal-title":"Cell Death Dis."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0020","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1179\/016164109X12590518685660","article-title":"A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis","volume":"32","author":"Collin","year":"2010","journal-title":"Neurol. Res."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0025","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1177\/1352458510378020","article-title":"Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis","volume":"16","author":"Kavia","year":"2010","journal-title":"Mult. Scler. J."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0030","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2337\/dc09-1029","article-title":"Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal produce (Sativex) in painful diabetic neuropathy","volume":"33","author":"Selvarajah","year":"2010","journal-title":"Diabetes Care"},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0035","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1177\/1352458510367462","article-title":"Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis","volume":"16","author":"Wade","year":"2010","journal-title":"Mult. Scler. J."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0040","first-page":"259","article-title":"Biotransformation of cannabidiol in mice. Identification of new acid metabolites","volume":"5","author":"Martin","year":"1977","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0045","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3109\/00498259009046849","article-title":"Metabolites of cannabidiol identified in human urine","volume":"20","author":"Harvey","year":"1990","journal-title":"Xenobiotica"},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0050","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.lfs.2011.05.018","article-title":"Identification of cytochrome P450 enzymes responsible for cannabidiol by human liver microsomes","volume":"89","author":"Jiang","year":"2011","journal-title":"Life Sci."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0055","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1006\/abbi.1993.1506","article-title":"Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and (S)-mephenytoin 4\u2032-hydroxylation","volume":"306","author":"Wrighton","year":"1993","journal-title":"Arch. Biochem. Biophys."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0060","first-page":"1081","article-title":"Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes","volume":"24","author":"Karam","year":"1996","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0065","first-page":"805","article-title":"Identification of the human P450 enzymes involved in lansoprazole metabolism","volume":"277","author":"Pearce","year":"1996","journal-title":"J. Pharmacol Exp. Ther."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0070","first-page":"1401","article-title":"Role of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite","volume":"24","author":"Bajpai","year":"1996","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0075","first-page":"133","article-title":"Diazepam metabolism by cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as Low Km diazepam N-demethylases","volume":"25","author":"Jung","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0080","first-page":"1102","article-title":"Escitalopram (s-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to r-citalopram","volume":"29","author":"von Moltke","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0085","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/dmd.109.029132","article-title":"Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogerol to its pharmacologically active metabolite","volume":"38","author":"Kazui","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0090","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects","volume":"108","author":"Hulot","year":"2006","journal-title":"Blood"},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0095","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","article-title":"Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamics response to clopidogrel but not prasugrel","volume":"5","author":"Brandt","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0100","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1476-5381.1972.tb08092.x","article-title":"A metabolic interaction in vivo between cannabidiol and \u03941-tetrahydrocannabinol","volume":"45","author":"Jones","year":"1972","journal-title":"Br. J. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0105","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/clpt.1980.139","article-title":"Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction","volume":"28","author":"Benowitz","year":"1980","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0110","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3109\/00498259609046707","article-title":"Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes","volume":"26","author":"Jaeger","year":"1996","journal-title":"Xenobiotica"},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0115","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.bcp.2010.01.028","article-title":"Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes","volume":"79","author":"Yamaori","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0120","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.lfs.2011.02.017","article-title":"Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety","volume":"88","author":"Yamaori","year":"2011","journal-title":"Life Sci."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0125","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11419-011-0112-7","article-title":"Differential inhibition of human cytochrome P450 2A6 and 2B6 by major phytocannabinoids","volume":"29","author":"Yamaori","year":"2011","journal-title":"Forensic Toxicol."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0130","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1124\/dmd.111.041384","article-title":"Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6","volume":"39","author":"Yamaori","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0135","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2133\/dmpk.DMPK-11-RG-107","article-title":"Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity","volume":"27","author":"Yamaori","year":"2012","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0140","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1248\/cpb.16.822","article-title":"Forensic chemical study on marihuana. I. A detection method of the principal constituents by thin-layer and gas chromatographies","volume":"16","author":"Aramaki","year":"1968","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0145","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1248\/cpb.38.1697","article-title":"In vivo and in vitro metabolism of cannabidiol monomethyl ether and cannabidiol dimethyl ether in the guinea pig: on the formation mechanism of cannabielsoin-type metabolite from cannabidiol","volume":"38","author":"Gohda","year":"1990","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0150","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1016\/0006-2952(87)90313-3","article-title":"Self-catalyzed inactivation of cytochrome P-450 during microsomal metabolism of cannabidiol","volume":"36","author":"Watanabe","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0155","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/BF02440859","article-title":"Development and preliminary application of a simple assay of (S)-mephenytoin 4-hydroxylase activity in human liver microsomes","volume":"44","author":"Chiba","year":"1993","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0160","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1124\/dmd.106.014472","article-title":"Evaluation of 3-O-Methylfluorescein as a selective fluorometric substrate for CYP2C19 in human liver microsomes","volume":"35","author":"Sudsakorn","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0165","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.105.093229","article-title":"The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions","volume":"316","author":"Obach","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0170","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1023\/A:1007509324428","article-title":"Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver","volume":"17","author":"Kanamitsu","year":"2000","journal-title":"Pharm. Res."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0175","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archgenpsychiatry.2008.519","article-title":"Distinct effects of delta 9-tetra-hydrocannabinol and cannabidiol on neural activation during emotional processing","volume":"66","author":"Fusar-Poli","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0180","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200342040-00003","article-title":"Pharmacokinetics and pharmacodynamics of cannabinoids","volume":"42","author":"Grotenhermen","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0185","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/dmd.30.3.235","article-title":"(+)-N-3-Benzyl-nirvanol and (\u2014)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19","volume":"30","author":"Suzuki","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0190","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1124\/dmd.32.6.584","article-title":"Validation of (\u2014)-N-3-benzyl-phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes","volume":"32","author":"Cai","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0195","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.32.8.821","article-title":"Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities","volume":"32","author":"Li","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0200","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1124\/dmd.107.019265","article-title":"CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles","volume":"36","author":"Foti","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0205","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1124\/dmd.30.5.602","article-title":"Metabolism of (+)- and (\u2014)-limonenes to respective carveols and perillyl alcohols by CYP2C9 and CYP2C19 in human liver microsomes","volume":"30","author":"Miyazawa","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0210","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/026988119300700112","article-title":"Effects of ipsapirone and cannabidiol on human experimental anxiety","volume":"7","author":"Zuardi","year":"1993","journal-title":"J. Psychopharmacol."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0215","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0220","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1590\/S0100-879X2006000400001","article-title":"Cannabidiol, a cannabis sativa constituent, as an antipsychotic drug","volume":"39","author":"Zuardi","year":"2006","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0225","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00004714-200104000-00007","article-title":"Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers","volume":"21","author":"Harvey","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0230","first-page":"624","article-title":"Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydro-cannabinol and its relationship to pharmacological potency","volume":"255","author":"Thomas","year":"1990","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0235","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0091-3057(91)90357-8","article-title":"Assay of plasma cannabidiol by capillary gas chromatography\/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans","volume":"40","author":"Consroe","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0240","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1345\/aph.17296","article-title":"Ticlopidine-induced phenytoin toxicity","volume":"32","author":"Klaassen","year":"1998","journal-title":"Ann. Pharmacother."},{"key":"10.2133\/dmpk.DMPK-12-RG-129_bb0245","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1111\/j.1528-1157.1995.tb06007.x","article-title":"Cytochrome P450 isozymes and antiepileptic drug interactions","volume":"36","author":"Levy","year":"1995","journal-title":"Epilepsia"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715304225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715304225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T10:00:23Z","timestamp":1562580023000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436715304225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"alternative-id":["S1347436715304225"],"URL":"https:\/\/doi.org\/10.2133\/dmpk.dmpk-12-rg-129","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2013]]}}}